These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38055253)

  • 1. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
    Moore KN; Angelergues A; Konecny GE; García Y; Banerjee S; Lorusso D; Lee JY; Moroney JW; Colombo N; Roszak A; Tromp J; Myers T; Lee JW; Beiner M; Cosgrove CM; Cibula D; Martin LP; Sabatier R; Buscema J; Estévez-García P; Coffman L; Nicum S; Duska LR; Pignata S; Gálvez F; Wang Y; Method M; Berkenblit A; Bello Roufai D; Van Gorp T;
    N Engl J Med; 2023 Dec; 389(23):2162-2174. PubMed ID: 38055253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.
    Moore KN; Oza AM; Colombo N; Oaknin A; Scambia G; Lorusso D; Konecny GE; Banerjee S; Murphy CG; Tanyi JL; Hirte H; Konner JA; Lim PC; Prasad-Hayes M; Monk BJ; Pautier P; Wang J; Berkenblit A; Vergote I; Birrer MJ
    Ann Oncol; 2021 Jun; 32(6):757-765. PubMed ID: 33667670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
    O'Malley DM; Matulonis UA; Birrer MJ; Castro CM; Gilbert L; Vergote I; Martin LP; Mantia-Smaldone GM; Martin AG; Bratos R; Penson RT; Malek K; Moore KN
    Gynecol Oncol; 2020 May; 157(2):379-385. PubMed ID: 32081463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.
    Moore KN; Martin LP; O'Malley DM; Matulonis UA; Konner JA; Perez RP; Bauer TM; Ruiz-Soto R; Birrer MJ
    J Clin Oncol; 2017 Apr; 35(10):1112-1118. PubMed ID: 28029313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.
    Moore KN; O'Malley DM; Vergote I; Martin LP; Gonzalez-Martin A; Malek K; Birrer MJ
    Gynecol Oncol; 2018 Oct; 151(1):46-52. PubMed ID: 30093227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine.
    Martin LP; Konner JA; Moore KN; Seward SM; Matulonis UA; Perez RP; Su Y; Berkenblit A; Ruiz-Soto R; Birrer MJ
    Gynecol Oncol; 2017 Nov; 147(2):402-407. PubMed ID: 28843653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
    Gilbert L; Oaknin A; Matulonis UA; Mantia-Smaldone GM; Lim PC; Castro CM; Provencher D; Memarzadeh S; Method M; Wang J; Moore KN; O'Malley DM
    Gynecol Oncol; 2023 Mar; 170():241-247. PubMed ID: 36736157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine.
    Matulonis UA; Birrer MJ; O'Malley DM; Moore KN; Konner J; Gilbert L; Martin LP; Bauer TM; Oza AM; Malek K; Pinkas J; Kim SK
    Clin Cancer Res; 2019 Mar; 25(6):1727-1736. PubMed ID: 30413525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer.
    Moore KN; Vergote I; Oaknin A; Colombo N; Banerjee S; Oza A; Pautier P; Malek K; Birrer MJ
    Future Oncol; 2018 Jul; 14(17):1669-1678. PubMed ID: 29424243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer.
    Bogani G; Coleman RL; Vergote I; van Gorp T; Ray-Coquard I; Oaknin A; Matulonis U; O'Malley D; Raspagliesi F; Scambia G; Monk BJ
    Int J Gynecol Cancer; 2024 Apr; 34(4):469-477. PubMed ID: 38101816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic strategies targeting folate receptor α for ovarian cancer.
    Mai J; Wu L; Yang L; Sun T; Liu X; Yin R; Jiang Y; Li J; Li Q
    Front Immunol; 2023; 14():1254532. PubMed ID: 37711615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study.
    Matulonis UA; Lorusso D; Oaknin A; Pignata S; Dean A; Denys H; Colombo N; Van Gorp T; Konner JA; Marin MR; Harter P; Murphy CG; Wang J; Noble E; Esteves B; Method M; Coleman RL
    J Clin Oncol; 2023 May; 41(13):2436-2445. PubMed ID: 36716407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.
    Moore KN; Martin LP; O'Malley DM; Matulonis UA; Konner JA; Vergote I; Ponte JF; Birrer MJ
    Future Oncol; 2018 Jan; 14(2):123-136. PubMed ID: 29098867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer.
    Dilawari A; Shah M; Ison G; Gittleman H; Fiero MH; Shah A; Hamed SS; Qiu J; Yu J; Manheng W; Ricks TK; Pragani R; Arudchandran A; Patel P; Zaman S; Roy A; Kalavar S; Ghosh S; Pierce WF; Rahman NA; Tang S; Mixter BD; Kluetz PG; Pazdur R; Amiri-Kordestani L
    Clin Cancer Res; 2023 Oct; 29(19):3835-3840. PubMed ID: 37212825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and toxicity of mirvetuximab soravtansine, a novel antibody-drug conjugate, in the treatment of advanced or recurrent ovarian cancer: a meta-analysis.
    Xu K; Wang T; Pan S; He J
    Expert Rev Clin Pharmacol; 2023; 16(11):1141-1152. PubMed ID: 37771164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mirvetuximab Soravtansine: First Approval.
    Heo YA
    Drugs; 2023 Feb; 83(3):265-273. PubMed ID: 36656533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mirvetuximab Soravtansine Combination Yields Encouraging Response Rates in Ovarian Cancer.
    Fowler M
    Oncology (Williston Park); 2020 Jul; 34(7):250. PubMed ID: 32674207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer.
    Yam C; Rauch GM; Rahman T; Karuturi M; Ravenberg E; White J; Clayborn A; McCarthy P; Abouharb S; Lim B; Litton JK; Ramirez DL; Saleem S; Stec J; Symmans WF; Huo L; Damodaran S; Sun R; Moulder SL
    Invest New Drugs; 2021 Apr; 39(2):509-515. PubMed ID: 32984932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models.
    Ponte JF; Ab O; Lanieri L; Lee J; Coccia J; Bartle LM; Themeles M; Zhou Y; Pinkas J; Ruiz-Soto R
    Neoplasia; 2016 Dec; 18(12):775-784. PubMed ID: 27889646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
    Pujade-Lauraine E; Fujiwara K; Ledermann JA; Oza AM; Kristeleit R; Ray-Coquard IL; Richardson GE; Sessa C; Yonemori K; Banerjee S; Leary A; Tinker AV; Jung KH; Madry R; Park SY; Anderson CK; Zohren F; Stewart RA; Wei C; Dychter SS; Monk BJ
    Lancet Oncol; 2021 Jul; 22(7):1034-1046. PubMed ID: 34143970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.